Detalhe da pesquisa
1.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403819
2.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Med
; 3(11): 760-773.e5, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998623
3.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691871
4.
Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
BMC Cancer
; 9: 262, 2009 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-19643007
5.
Immunoglobulin E-dependent regulation of the CCR3 chemokine receptor by interferon-gamma in atopic asthmatics.
Int Arch Allergy Immunol
; 148(3): 219-27, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18849613
6.
HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.
Semin Oncol
; 45(1-2): 27-33, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318081
7.
Tratamiento con HeberFERON( en el carcinoma basal palpebral
Rev. cuba. oftalmol
; 36(2)jun. 2023.
Artigo
em Espanhol
|
LILACS-Express
| ID: biblio-1550923
8.
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
BMC Pharmacol Toxicol
; 17(1): 58, 2016 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27923408
9.
Seguridad del HeberFERON( en pacientes con carcinoma basal palpebral / Safety of HeberFERON in patients with basal cell eyelid carcinoma
Rev. cuba. oftalmol
; 34(1): e1131, 2021. tab
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-1289530
10.
Respuesta clínica del tratamiento con HerberFERON( en pacientes con carcinoma basal palpebral / Clinical response to treatment with HerberFERON® in patients with basal palpebral carcinoma
Rev. cuba. oftalmol
; 34(1): e1139, 2021. tab
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-1289532
11.
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
BMC Pharmacol Toxicol
; 13: 20, 2012 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23272809
12.
Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior® / Safety and response to treatment of compassionate use of an anti-CD20 monoclonal antibody CIMABior®
Rev. cuba. hematol. inmunol. hemoter
; 33(4): 35-49, oct.-dic. 2017. tab
Artigo
em Espanhol
| LILACS | ID: biblio-960435
13.
Seguridad de la aplicación intravenosa del cigb-300 en pacientes con hemopatías malignas. Estudio EHPMA / Red blood cell antigens and antibodies in patients awaiting renal transplantation
Rev. cuba. hematol. inmunol. hemoter
; 32(2): 236-248, abr.-jun. 2016. ilus, tab
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-908289
14.
Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
Biopharm Drug Dispos
; 26(4): 151-9, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15799006